Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) – Pipeline Review, H2 2017’, provides in depth analysis on Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology and Infectious Disease under development targeting Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)

The report reviews Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics and enlists all their major and minor projects

The report assesses Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Aduro BioTech Inc

Agenus Inc

Alligator Bioscience AB

Bristol-Myers Squibb Company

Cold Genesys Inc

Crown Bioscience Inc

Five Prime Therapeutics Inc

Globavir Biosciences Inc

Humorigin Biotechnology Corp

Immunocore Ltd

Immunwork Inc

Innovent Biologics Inc

JHL Biotech Inc

MacroGenics Inc

MedImmune LLC

Merck & Co Inc

OncoImmune Inc

Premier Biomedical Inc

Serometrix LLC

Sutro Biopharma Inc

Tikcro Technologies Ltd

Xencor Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Overview 10

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Development 11

Products under Development by Stage of Development 11

Products under Development by Therapy Area 12

Products under Development by Indication 13

Products under Development by Companies 17

Products under Development by Universities/Institutes 29

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Therapeutics Assessment 31

Assessment by Mechanism of Action 31

Assessment by Route of Administration 33

Assessment by Molecule Type 35

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Companies Involved in Therapeutics Development 37

Aduro BioTech Inc 37

Agenus Inc 38

Alligator Bioscience AB 39

Bristol-Myers Squibb Company 40

Cold Genesys Inc 43

Crown Bioscience Inc 43

Five Prime Therapeutics Inc 44

Globavir Biosciences Inc 44

Humorigin Biotechnology Corp 45

Immunocore Ltd 45

Immunwork Inc 46

Innovent Biologics Inc 46

JHL Biotech Inc 47

MacroGenics Inc 48

MedImmune LLC 49

Merck & Co Inc 51

OncoImmune Inc 51

Premier Biomedical Inc 52

Serometrix LLC 52

Sutro Biopharma Inc 53

Tikcro Technologies Ltd 53

Xencor Inc 54

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Drug Profiles 55

10B-10 - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

AGEN-1884 - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

AGEN-2041 - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

Antisense Oligonucleotide to Inhibit CTLA4 for Melanoma - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

ATOR-1015 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

Biologic to Antagonize CTLA4 and PD-1 for Solid Tumor - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

Biologic to Antagonize CTLA4 for Solid Tumor - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

Bispecific Monoclonal Antibodies to Antagonize PD-1 and CTLA-4 for Solid Tumor and Hematological Tumor - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

Bispecific Monoclonal Antibody to Antagonize CTLA-4 for Oncology - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

Bispecific Monoclonal Antibody to Target CTLA-4 and LAG-3 for Oncology - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

CG-0070 + Immune Checkpoint Modulator - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

CG-0161 - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

CNC-225 + CNC-118 + Anti-CTLA-4 - Drug Profile 68

Product Description 68

Mechanism Of Action 68

R&D Progress 68

durvalumab + IMCgp-100 + tremelimumab - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

durvalumab + tremelimumab - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

FPT-155 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

HOR-010 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

IBI-310 - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

ipilimumab - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

ipilimumab + nivolumab - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

JMW-3B3 - Drug Profile 98

Product Description 98

Mechanism Of Action 98

R&D Progress 98

KN-044 - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

MEDI-0562 + tremelimumab - Drug Profile 100

Product Description 100

Mechanism Of Action 100

R&D Progress 100

MEDI-3617 + tremelimumab - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

MK-1308 - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

Monoclonal Antibodies to Antagonize 1 PD-1 and CTLA-4 for Solid Tumor and Hematological Tumor - Drug Profile 103

Product Description 103

Mechanism Of Action 103

R&D Progress 103

Monoclonal Antibodies to Antagonize CTLA-4 for Metastatic Melanoma - Drug Profile 104

Product Description 104

Mechanism Of Action 104

R&D Progress 104

Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile 105

Product Description 105

Mechanism Of Action 105

R&D Progress 105

Monoclonal Antibody to Antagonize CTLA4 for Oncology - Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

Monoclonal Antibody to Inhibit CTLA-4 for Oncology - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

Monoclonal Antibody to Inhibit CTLA4 for Breast Cancer - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

ONC-392 - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

Small Molecule to Antagonize CTLA-4 for Oncology - Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

Small Molecules to Inhibit CTLA4 for Oncology - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

SNCA-21 - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

TE-1254 - Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

tremelimumab - Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

XmAb-20717 - Drug Profile 118

Product Description 118

Mechanism Of Action 118

R&D Progress 118

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Dormant Products 119

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Discontinued Products 121

Cytotoxic T Lymphocyte Protein 4 (Cytotoxic T Lymphocyte Associated Antigen 4 or CD152 or CTLA4) - Product Development Milestones 122

Featured News & Press Releases 122

Aug 15, 2017: Bristol-Myers Squibb Announces Topline Results from CheckMate -214, a Phase 3 Study of Opdivo in Combination with Yervoy in Intermediate and Poor-Risk Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma 122

Jul 27, 2017: AstraZeneca reports initial results from the ongoing MYSTIC trial in Stage IV lung cancer 122

Jul 26, 2017: NICE approval for nivolumab provides new treatment for advanced blood cancer 123

Jul 24, 2017: U.S. Food and Drug Administration Expands Approval of Yervoy (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma 123

Jul 08, 2017: Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015 125

Jul 05, 2017: Combo immunotherapy may herald new standard of care for kidney cancer 125

Jun 05, 2017: Agenus anti-CTLA-4 antibody shows strong safety and tolerability 126

Jun 04, 2017: New Data Evaluating the Safety and Preliminary Relapse-Free Survival of Adjuvant Yervoy (ipilimumab) 3 mg/kg and 10 mg/kg in Resected High-Risk Melanoma Patients Presented at ASCO 126

Jun 04, 2017: Combination therapy shown to shrink tumours in many advanced melanoma patients whose cancer has spread to the brain 127

Jun 04, 2017: First Presentation of Efficacy Data from CheckMate-204 Evaluating the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Demonstrates Anti-tumor Activity in Advanced Melanoma Patients with Brain Metastases 128

Jun 03, 2017: Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrated Promising Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer in Phase 2 CheckMate -142 Study 129

May 22, 2017: Agenus to present safety results for anti-CTLA-4 antibody at ASCO 2017 Annual Meeting 130

May 04, 2017: Alligator Bioscience presents promising immuno-oncology data at US conference; - Strong new preclinical findings for ATOR-1015 131

Apr 28, 2017: Alligator Bioscience to present new pre-clinical data for ATOR-1015 at PEGS conference in Boston, May 4 131

Apr 04, 2017: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibbs Application for Opdivo in Previously Treated dMMR or MSI-H Metastatic Colorectal Cancer 131

Appendix 133

Methodology 133

Coverage 133

Secondary Research 133

Primary Research 133

Expert Panel Validation 133

Contact Us 133

Disclaimer 134

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 11

Number of Products under Development by Therapy Areas, H2 2017 12

Number of Products under Development by Indications, H2 2017 13

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 16

Number of Products under Development by Companies, H2 2017 17

Number of Products under Development by Companies, H2 2017 (Contd..1) 18

Products under Development by Companies, H2 2017 19

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 20

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 21

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 22

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 23

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 24

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 25

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 26

Products under Development by Companies, H2 2017 (Contd..8), H2 2017 27

Products under Development by Companies, H2 2017 (Contd..9), H2 2017 28

Number of Products under Investigation by Universities/Institutes, H2 2017 29

Products under Investigation by Universities/Institutes, H2 2017 30

Number of Products by Stage and Mechanism of Actions, H2 2017 32

Number of Products by Stage and Route of Administration, H2 2017 34

Number of Products by Stage and Molecule Type, H2 2017 36

Pipeline by Aduro BioTech Inc, H2 2017 37

Pipeline by Agenus Inc, H2 2017 38

Pipeline by Alligator Bioscience AB, H2 2017 39

Pipeline by Bristol-Myers Squibb Company, H2 2017 40

Pipeline by Cold Genesys Inc, H2 2017 43

Pipeline by Crown Bioscience Inc, H2 2017 43

Pipeline by Five Prime Therapeutics Inc, H2 2017 44

Pipeline by Globavir Biosciences Inc, H2 2017 44

Pipeline by Humorigin Biotechnology Corp, H2 2017 45

Pipeline by Immunocore Ltd, H2 2017 45

Pipeline by Immunwork Inc, H2 2017 46

Pipeline by Innovent Biologics Inc, H2 2017 46

Pipeline by JHL Biotech Inc, H2 2017 47

Pipeline by MacroGenics Inc, H2 2017 48

Pipeline by MedImmune LLC, H2 2017 49

Pipeline by Merck & Co Inc, H2 2017 51

Pipeline by OncoImmune Inc, H2 2017 51

Pipeline by Premier Biomedical Inc, H2 2017 52

Pipeline by Serometrix LLC, H2 2017 52

Pipeline by Sutro Biopharma Inc, H2 2017 53

Pipeline by Tikcro Technologies Ltd, H2 2017 53

Pipeline by Xencor Inc, H2 2017 54

Dormant Products, H2 2017 119

Dormant Products, H2 2017 (Contd..1), H2 2017 120

Discontinued Products, H2 2017 121

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 11

Number of Products under Development by Therapy Areas, H2 2017 12

Number of Products under Development by Top 10 Indications, H2 2017 13

Number of Products by Mechanism of Actions, H2 2017 31

Number of Products by Stage and Mechanism of Actions, H2 2017 31

Number of Products by Routes of Administration, H2 2017 33

Number of Products by Stage and Routes of Administration, H2 2017 33

Number of Products by Top 10 Molecule Types, H2 2017 35

Number of Products by Stage and Top 10 Molecule Types, H2 2017 35

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports